SAN FRANCISCO, May 2, 2017 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) will announce its financial
results for the first quarter ended March 31, 2017,
on Tuesday, May 9, 2017, after the close of U.S.-based
financial markets. Howard Robin, president and chief executive
officer, will host a conference call to review the results
beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m.
Pacific Time (PT).
The press release and a live audio-only Webcast of the
conference call can be accessed through a link that is posted on
the home page and Investors section of the Nektar
website: http://www.nektar.com. The web broadcast of the
conference call will be available for replay through Monday,
June 12, 2017.
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 8518262 (Nektar Therapeutics is the
host)
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage
biopharmaceutical company whose mission is to discover and develop
innovative medicines to address the unmet medical needs of
patients. Our R&D pipeline of new investigational medicines
includes treatments for cancer, auto-immune disease and chronic
pain. We leverage Nektar's proprietary and proven chemistry
platform in the discovery and design of our new therapeutic
candidates. Nektar is headquartered in San
Francisco, California, with additional operations
in Huntsville, Alabama and Hyderabad, India.
Further information about the company and its drug development
programs and capabilities may be found online
at http://www.nektar.com.
Contact:
For Investors and Media:
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-first-quarter-of-2017-on-tuesday-may-9-2017-after-close-of-us-based-financial-markets-300449323.html
SOURCE Nektar Therapeutics